Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease

29 Jul 2017

Abstract excerpt

In the translation of discoveries from the laboratory to the clinic, the track record in developing disease-modifying therapies in neurodegenerative disease is poor. A carefully designed development pipeline built from discoveries in both pre-clinical models and patient populations is necessary to optimize the chances for success. Genetic variation in the leucine-rich repeat kinase two gene (LRRK2) is linked to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Parkinson's Disease Mechanisms and Treatments
Share to Plant biochemistry and biosynthesis

Source

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Identifiers

PMID: 28764903
DOI: 10.1016/j.expneurol.2017.07.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson diseasePMID 28764903Read ↗

Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to dateSemantic proximity Read ↗

The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.Semantic proximity Read ↗

Exploring LRRK2-dependent Mechanisms in Parkinson's Disease Therapy.Semantic proximity Read ↗

Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic.Semantic proximity Read ↗

Recent advances in targeting LRRK2 for Parkinson's disease treatment.Semantic proximity Read ↗

LRRK2 pathobiology in Parkinson's disease.Semantic proximity Read ↗

LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review.Semantic proximity Read ↗

Targeting LRRK2 in Parkinson's disease: an update on recent developments.Semantic proximity Read ↗

A step forward for LRRK2 inhibitors in Parkinson's disease.Semantic proximity Read ↗

Leucine-Rich Repeat Kinase 2 in Parkinson’s Disease: Updated from Pathogenesis to Potential Therapeutic TargetSemantic proximity Read ↗

The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease.Semantic proximity Read ↗

Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.